Back to search results

STC-15 with Toripalimab for Advanced Cancers and STC-15 Monotherapy for Sarcomas

This study is testing STC-15, a new medication, in two ways. For certain advanced cancers, STC-15 is given along with toripalimab. For specific types of sarcoma (a cancer that starts in tissues like bone or muscle), including dedifferentiated liposarcoma and leiomyosarcoma, STC-15 is given alone. The main goals are to see how safe these treatments are and if they help shrink tumors. You might be able to join if you are at least 18 years old, have a good general health status (ECOG performance status 0 or 1), and your cancer has progressed on prior treatments. The study aims to enroll 107 participants.

Study design
This is an early phase interventional study. The monotherapy part for sarcomas is open-label, meaning you and your doctors will know which treatment you are receiving, and it is not randomized.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure safety and tumor activity at 6 months for different parts of the trial.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06975293

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

Recruiting
PHASE1Ages 18+InterventionalTreatment
STORM Therapeutics LTD
~107 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:STC-15 in combination with toripalimabSTC-15 monotherapy

At a glance

Recruiting sites
9 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Combination Cohorts: Safety and tolerability of STC-15 in combination with toripalimab
Measured over 6 months
+1 more outcome measured

Conditions

Solid Tumor
Sarcoma
Leiomyosarcoma
Dedifferentiated Liposarcoma

Explore related trials

Dedifferentiated LiposarcomaLeiomyosarcomaSarcomaSolid Neoplasm

Where it's being run

10 sites across 6 states
Texas5
California1
Massachusetts1
Michigan1
New York1
Virginia1

Study leadership

  • Sandra Tong, MD · STUDY_DIRECTOR · Storm Therapeutics

Who to contact

Sandra Tong, MD
[email protected]
650-399-6357
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Estimated life expectancy ≥ 3 months.
ECOG performance status 0 or 1.
Measurable disease according to RECIST v1.1 as assessed by the local site investigator/radiology.
Documented radiologic assessment of progression on the prior therapy before study entry.
Have adequate organ function.
Have the ability to swallow, retain, and absorb oral medication.
Have histologic or cytologic confirmation of advanced sarcoma of the selected histologic subtype that is not amenable to local curative therapy. Participant must have received at least 2, but no more than 4 prior lines of systemic therapy.
Pre-treatment and on-treatment biopsy if medically feasible.

Exclusion

Pregnant and lactating women.
Received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives, whichever is shorter, prior to first IMP administration.
Participants who have not recovered from all AEs due to previous therapies to Grade ≤ 1 or baseline, according to NCI-CTCAE v5.0. Exceptions include: alopecia, Grade ≤ 2 neuropathy, and endocrine-related AEs Grade ≤ 2 who are stable on treatment or hormone replacement.
History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or the presence of ongoing pneumonitis/interstitial lung disease).
Clinically significant cardiovascular disease or condition.
Known active CNS metastases and/or leptomeningeal disease.

What this trial measures

  • Combination Cohorts: Safety and tolerability of STC-15 in combination with toripalimab6 months

    Incidence of adverse events graded according to CTCAE v5.0

  • Phase 2 Monotherapy Cohorts: Antitumor activity of STC-15 monotherapy6 months

    ORR according to RECIST